Jonathan Young Akero Therapeutics, Inc. (AKRO) insider trading activity

Jonathan Young is Chief Operating Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 226,286 shares of AKRO, which is worth approximately $6.39 Million. The most recent transaction as insider was on Oct 01, 2024, when has been sold 10,000 shares (Common Stock) at a price of $28.18 per share, resulting in proceeds of $281,800. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 226K

8.33% 3M change

23.53% 12M change

Total Value Held $6.39 Million

Jonathan Young Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 01 2024	SELL Open market or private sale	$281,800 $28.18 p/Share	10,000 Reduced 4.23%	226,286 Common Stock
Sep 10 2024	SELL Open market or private sale	$14,870 $26.18 p/Share	568 Reduced 0.24%	236,286 Common Stock
Sep 03 2024	SELL Open market or private sale	$135,000 $27.0 p/Share	5,000 Reduced 2.07%	236,854 Common Stock
Aug 01 2024	SELL Open market or private sale	$134,200 $26.84 p/Share	5,000 Reduced 2.03%	241,854 Common Stock
Jul 01 2024	SELL Open market or private sale	$117,000 $23.4 p/Share	5,000 Reduced 1.99%	246,854 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$21,216 $19.94 p/Share	1,064 Added 0.42%	251,854 Common Stock
Jun 11 2024	SELL Open market or private sale	$56,962 $22.64 p/Share	2,516 Reduced 0.99%	250,790 Common Stock
Jun 03 2024	SELL Open market or private sale	$96,450 $19.29 p/Share	5,000 Reduced 1.94%	253,306 Common Stock
May 01 2024	SELL Open market or private sale	$100,750 $20.15 p/Share	5,000 Reduced 1.9%	258,306 Common Stock
Apr 01 2024	SELL Open market or private sale	$10,008 $25.02 p/Share	400 Reduced 0.15%	263,306 Common Stoek
Apr 01 2024	SELL Open market or private sale	$111,917 $24.33 p/Share	4,600 Reduced 1.71%	263,706 Common Stock
Mar 13 2024	SELL Open market or private sale	$18,442 $28.33 p/Share	651 Reduced 0.24%	268,306 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$51,659 $0.62 p/Share	83,321 Added 23.65%	268,957 Common Stock
Dec 27 2023	SELL Open market or private sale	$129,936 $24.0 p/Share	5,414 Reduced 2.84%	185,131 Common Stock
Dec 27 2023	BUY Exercise of conversion of derivative security	$34,433 $6.36 p/Share	5,414 Added 2.76%	190,545 Common Stock
Dec 14 2023	SELL Open market or private sale	$11,272 $20.76 p/Share	543 Reduced 0.29%	185,131 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	32,497 Added 14.9%	185,674 Common Stock
Nov 17 2023	SELL Open market or private sale	$440,400 $14.68 p/Share	30,000 Reduced 16.38%	153,177 Common Stock
Oct 02 2023	SELL Open market or private sale	$25,039 $51.1 p/Share	490 Reduced 0.27%	183,177 Common Stock
Oct 02 2023	BUY Exercise of conversion of derivative security	$10,339 $21.1 p/Share	490 Added 0.27%	183,667 Common Stock
Sep 13 2023	SELL Open market or private sale	$28,291 $50.34 p/Share	562 Reduced 0.31%	183,177 Common Stock
Jun 13 2023	SELL Open market or private sale	$29,676 $55.16 p/Share	538 Reduced 0.29%	183,739 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$27,559 $43.47 p/Share	634 Reduced 0.34%	184,277 Common Stock
Jan 03 2023	SELL Open market or private sale	$479,575 $54.64 p/Share	8,777 Reduced 4.53%	184,911 Common Stock
Jan 03 2023	BUY Exercise of conversion of derivative security	$5,441 $0.62 p/Share	8,777 Added 4.34%	193,688 Common Stock

Jonathan Young

Chief Operating Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account